ESC 365 - The selective rho kinase inhibitor trans-6-((4-aminocyclohexyl)amino)-5-fluoro-2-methoxynicotinamide ameliorates monocrotaline-induced pulmonary hypertension

ESC Premium Access

The selective rho kinase inhibitor trans-6-((4-aminocyclohexyl)amino)-5-fluoro-2-methoxynicotinamide ameliorates monocrotaline-induced pulmonary hypertension

Session: Poster session 1 - Understanding the pulmonary circulation

Topic: Chronic pulmonary hypertension

Speaker: Doctor S. Cantoni (Parma, IT)

Event: ESC Congress 2017

Congress Presentation

Add to my library

About the speaker

Doctor Silvia Cantoni

R&D Chiesi Farmaceutici S.P.A., Parma (Italy)

0 follower

13 more presentations in this session

Increased central venous pressure is provoked not by pulmonary-circulation defects but by mild cardiac-strains in patients after Fontan procedure.

Speaker: Doctor Y. Hamamichi (Tokyo, JP)

Different hemodynamic profiles to exercise in COPD and IPF candidates to lung transplantation: role of the pulmonary arterial stiffness

Speaker: Professor E. Peris Domingo (Barcelona, ES)

High-density lipoprotein cholesterol level as a predictor of long-term vasoreactivity in patients with idiopathic pulmonary arterial hypertension

Speaker: Doctor K. Jonas (Krakow, PL)

ACE gene subtypes and pulmonary hypertension among patients with chronic obstructive pulmonary disease

Speaker: Associate Professor C. Martiniuc (Chisinau, MD)

Mitochondrial permeability transition pore blocker prevents right ventricular mitochondrial damage in monocrtaline-induced pulmonary hypertension

Speaker: Doctor D. Lee (Goyang, KR)

Access the full session

Poster session 1 - Understanding the pulmonary circulation

Speakers: Doctor S. Cantoni, Doctor Y. Hamamichi, Professor E. Peris Domingo, Doctor K. Jonas, Associate Professor C. Martiniuc...

About the event

ESC Congress 2017

26 August - 30 August 2017

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources